โ† Back to List
Module 5โ€ข0 Views

Annotated Case Report Form (TILA278-201)

July 12, 2026

๐Ÿ“š Part of the TILA-278 Regulatory Dossier โ€” Reader's Guide. This article shows the live document; edits to the source appear here automatically.

๐Ÿงช
Mock / simulation document

This is a mock / simulation document, made for a portfolio and for learning. The drug (GLPI-103), the sponsor, the people, and the data are all fictional. It is not a real regulatory submission and has no clinical, legal, or regulatory standing. What is real is the shape of the thing โ€” the document structure, the standards it follows, and the analysis methods; the content inside is illustrative.

๐Ÿ“„
About this document โ€” a plain-language guide

What it is. Annotated Case Report Form (TILA278-201)

Why it exists. Clinical study documentation supporting the efficacy and safety of the program.

How it is produced here. The numbers come straight from the study's simulated Phase 3 dataset โ€” they are calculated from the data, not typed in by hand. That is why you see the same figures repeated across the protocol, the analysis plan, the report, and the summaries: they all read from the same source.

Format & governing standard. โ€”


Annotated Case Report Form (TILA278-201)

Document ID: aCRF
Version: 1.0
Change History: 1.0 โ€” Initial issue.
Standard(s): CDISC CDASH/SDTM

Annotated Case Report Form (aCRF) โ€” TILA278-201

The CRF annotated with the SDTM variable and codelist mappings for TILA278-201, providing the collection-to-SDTM traceability required in the Define-XML package. CDISC CDASH/SDTM; Define-XML 2.1.

Comments (0)

No comments yet. Be the first to say something!